At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RGNX Regenxbio
Trading 03-11 13:48:19 EDT
9.45
-0.45
-4.55%
High9.80Low9.15Vol415.95K
Open9.80D1 Closing9.90Amplitude6.57%
Mkt Cap487.74MTradable Cap406.34MTotal Shares51.61M
T/O3.89MT/O Rate0.97%Tradable Shares43.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Regenxbio Reports 'Positive' Interim Data in Duchenne Trial
MT Newswires Live  ·  00:37
Regenxbio Reports 'Positive' Interim Data in Duchenne Trial
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Reuters  ·  03-11 23:59
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
TIPRANKS  ·  03-11 23:56
Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial
Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year
Reuters  ·  03-11 23:45
Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year
Regenxbio Inc - to Request Pre-Bla Meeting With FDA in Mid-2026
THOMSON REUTERS  ·  03-11 23:45
Regenxbio Inc - to Request Pre-Bla Meeting With FDA in Mid-2026
Regenxbio Inc - Pivotal Topline Data Expected in Q2 2026
THOMSON REUTERS  ·  03-11 23:45
Regenxbio Inc - Pivotal Topline Data Expected in Q2 2026
Regenxbio Reports New Positive Interim Data From Phase I/Ii Affinity Duchenne® Trial of Rgx-202
THOMSON REUTERS  ·  03-11 23:45
Regenxbio Reports New Positive Interim Data From Phase I/Ii Affinity Duchenne® Trial of Rgx-202
Regenxbio Inc - No Serious Adverse Events Observed in Phase I/Ii Study
THOMSON REUTERS  ·  03-11 23:45
Regenxbio Inc - No Serious Adverse Events Observed in Phase I/Ii Study
Regenxbio CMO Stephen Pakola named defendant in RGX-111 securities class action after 18% share drop
Reuters  ·  03-11 21:03
Regenxbio CMO Stephen Pakola named defendant in RGX-111 securities class action after 18% share drop
REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk
Dow Jones  ·  03-10 02:45
REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk
LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yet
Reuters  ·  03-09 23:49
LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yet
BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow
Reuters  ·  03-09 23:46
BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow
BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway
Reuters  ·  03-09 21:19
BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway
This biotech's stock is soaring after a 'polarizing' FDA official is stepping down
Dow Jones  ·  03-09 21:18
This biotech's stock is soaring after a 'polarizing' FDA official is stepping down
REGENXBIO Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-09 18:39
REGENXBIO Is Maintained at Buy by HC Wainwright & Co.
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
TIPRANKS  ·  03-09 18:15
Regenxbio price target lowered to $30 from $32 at H.C. Wainwright
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
TIPRANKS  ·  03-07
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
REGENXBIO Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  03-07
REGENXBIO Is Maintained at Overweight by Morgan Stanley
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Kura Oncology (KURA)
TIPRANKS  ·  03-06
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Kura Oncology (KURA)
Regenxbio price target lowered to $17 from $18 at Morgan Stanley
TIPRANKS  ·  03-06
Regenxbio price target lowered to $17 from $18 at Morgan Stanley

Introduction

Company Name.
Regenxbio
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Issue price:
--